UNSPSC 51112507: Cyclophosphamide

This classification denotes a nitrogen mustard compound and immunosuppressant with the molecular formula C7H15Cl2N2O2P.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8N3DW7272P, chemically known as 2h-1,3,2-oxazaphosphorine, 2-(bis(2-chloroethyl)amino)tetrahydro-, 2-oxide but more generally known as cyclophosphamide, which bears US NIH Compound Identifier 2907. European Medicines Agency schedules Cyclophosphamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06859MIG.

UNSPSC 51112507 Cyclophosphamide is a Commodity code that names a single pharmaceutical product — a chemotherapy agent — but state and local procurement activity under this code reflects broader pharmacy benefit management and pharmaceutical sourcing strategies rather than cyclophosphamide purchases in isolation. The Texas Health and Human Services Commission (HHS) issued a Request for Information on March 27, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program that would establish direct relationships between state pharmacy benefit programs and pharmaceutical manufacturers, including chemotherapy and other specialty medications, to improve prescription fulfillment efficiency and cost management outside traditional pharmacy benefit manager, group purchasing organization, and wholesaler channels. The RFI solicits vendor experience with direct contracting for self-insured employers and health plans, flexibility to negotiate net pricing models without rebates, and capacity to implement value-based or outcomes-based agreements. Issuing bodies pursuing this code include state health and human services agencies managing pharmacy benefit programs for employee groups, retirees, and state-administered health plans.

The code shows recent activity in Texas. The Texas HHS Commission's March 2026 RFI represents preliminary market intelligence gathering before a formal Request for Proposal, with no award values, budget ranges, set-aside designations, or response deadline firm at the RFI stage — the state was conducting foundational research on available solutions and vendor capabilities to inform subsequent formal solicitations rather than committing to specific contract amounts or durations at the time of posting.